Free Trial
→ PH: Do THESE 4 things to your bank account now … (From Weiss Ratings) (Ad)tc pixel Free TSTL Stock Alerts

Tristel (TSTL) Competitors

Tristel logo
GBX 420.84 +10.84 (+2.64%)
As of 05/5/2026 12:00 PM Eastern
Compare

TSTL vs. AMS, SPEC, BVC, AKR, and ODX

Should you be buying Tristel stock or one of its competitors? The main competitors of Tristel include Advanced Medical Solutions Group (AMS), INSPECS Group (SPEC), BATM Advanced Communications (BVC), Akers Biosciences (AKR), and Omega Diagnostics Group (ODX). These companies are all part of the "medical instruments & supplies" industry.

How does Tristel compare to Advanced Medical Solutions Group?

Advanced Medical Solutions Group (LON:AMS) and Tristel (LON:TSTL) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their risk, valuation, institutional ownership, earnings, media sentiment, dividends, profitability and analyst recommendations.

Advanced Medical Solutions Group has a beta of 0.633, meaning that its stock price is 37% less volatile than the S&P 500. Comparatively, Tristel has a beta of 0.289, meaning that its stock price is 71% less volatile than the S&P 500.

In the previous week, Advanced Medical Solutions Group's average media sentiment score of 1.58 beat Tristel's score of 0.00 indicating that Advanced Medical Solutions Group is being referred to more favorably in the media.

Company Overall Sentiment
Advanced Medical Solutions Group Very Positive
Tristel Neutral

Advanced Medical Solutions Group has higher revenue and earnings than Tristel. Tristel is trading at a lower price-to-earnings ratio than Advanced Medical Solutions Group, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Advanced Medical Solutions Group£228.94M2.27£11.22M£4.5253.19
Tristel£49.54M4.07£6.54M£16.2425.91

Tristel has a net margin of 15.88% compared to Advanced Medical Solutions Group's net margin of 4.35%. Tristel's return on equity of 23.64% beat Advanced Medical Solutions Group's return on equity.

Company Net Margins Return on Equity Return on Assets
Advanced Medical Solutions Group4.35% 3.87% 2.35%
Tristel 15.88%23.64%9.89%

Advanced Medical Solutions Group presently has a consensus price target of GBX 270.25, indicating a potential upside of 12.40%. Tristel has a consensus price target of GBX 400, indicating a potential downside of 4.95%. Given Advanced Medical Solutions Group's stronger consensus rating and higher probable upside, research analysts clearly believe Advanced Medical Solutions Group is more favorable than Tristel.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Advanced Medical Solutions Group
0 Sell rating(s)
1 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.75
Tristel
0 Sell rating(s)
1 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
2.00

Advanced Medical Solutions Group pays an annual dividend of GBX 2.68 per share and has a dividend yield of 1.1%. Tristel pays an annual dividend of GBX 14.20 per share and has a dividend yield of 3.4%. Advanced Medical Solutions Group pays out 59.3% of its earnings in the form of a dividend. Tristel pays out 87.4% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future.

33.2% of Advanced Medical Solutions Group shares are owned by institutional investors. Comparatively, 22.5% of Tristel shares are owned by institutional investors. 4.1% of Advanced Medical Solutions Group shares are owned by company insiders. Comparatively, 21.0% of Tristel shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Summary

Advanced Medical Solutions Group beats Tristel on 10 of the 17 factors compared between the two stocks.

How does Tristel compare to INSPECS Group?

Tristel (LON:TSTL) and INSPECS Group (LON:SPEC) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their analyst recommendations, risk, institutional ownership, dividends, profitability, earnings, valuation and media sentiment.

Tristel has a beta of 0.289, suggesting that its share price is 71% less volatile than the S&P 500. Comparatively, INSPECS Group has a beta of 1.674, suggesting that its share price is 67% more volatile than the S&P 500.

Tristel has higher earnings, but lower revenue than INSPECS Group. INSPECS Group is trading at a lower price-to-earnings ratio than Tristel, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Tristel£49.54M4.07£6.54M£16.2425.91
INSPECS Group£195.28M0.43-£4.11M-£8.06N/A

In the previous week, Tristel's average media sentiment score of 0.00 equaled INSPECS Group'saverage media sentiment score.

Company Overall Sentiment
Tristel Neutral
INSPECS Group Neutral

22.5% of Tristel shares are owned by institutional investors. Comparatively, 14.8% of INSPECS Group shares are owned by institutional investors. 21.0% of Tristel shares are owned by insiders. Comparatively, 21.0% of INSPECS Group shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Tristel has a net margin of 15.88% compared to INSPECS Group's net margin of -4.25%. Tristel's return on equity of 23.64% beat INSPECS Group's return on equity.

Company Net Margins Return on Equity Return on Assets
Tristel15.88% 23.64% 9.89%
INSPECS Group -4.25%-8.73%0.45%

Tristel currently has a consensus price target of GBX 400, suggesting a potential downside of 4.95%. INSPECS Group has a consensus price target of GBX 60, suggesting a potential downside of 28.14%. Given Tristel's higher possible upside, equities analysts clearly believe Tristel is more favorable than INSPECS Group.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Tristel
0 Sell rating(s)
1 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
2.00
INSPECS Group
0 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
3.00

Summary

Tristel beats INSPECS Group on 10 of the 14 factors compared between the two stocks.

How does Tristel compare to BATM Advanced Communications?

Tristel (LON:TSTL) and BATM Advanced Communications (LON:BVC) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their analyst recommendations, media sentiment, dividends, earnings, valuation, profitability, risk and institutional ownership.

Tristel has a beta of 0.289, suggesting that its stock price is 71% less volatile than the S&P 500. Comparatively, BATM Advanced Communications has a beta of 0.725, suggesting that its stock price is 28% less volatile than the S&P 500.

Tristel presently has a consensus price target of GBX 400, suggesting a potential downside of 4.95%. Given Tristel's higher possible upside, research analysts plainly believe Tristel is more favorable than BATM Advanced Communications.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Tristel
0 Sell rating(s)
1 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
2.00
BATM Advanced Communications
0 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
3.00

Tristel has higher earnings, but lower revenue than BATM Advanced Communications. BATM Advanced Communications is trading at a lower price-to-earnings ratio than Tristel, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Tristel£49.54M4.07£6.54M£16.2425.91
BATM Advanced Communications£123.20M0.38-£278.26K-£4.20N/A

In the previous week, Tristel's average media sentiment score of 0.00 equaled BATM Advanced Communications'average media sentiment score.

Company Overall Sentiment
Tristel Neutral
BATM Advanced Communications Neutral

Tristel has a net margin of 15.88% compared to BATM Advanced Communications' net margin of -14.90%. Tristel's return on equity of 23.64% beat BATM Advanced Communications' return on equity.

Company Net Margins Return on Equity Return on Assets
Tristel15.88% 23.64% 9.89%
BATM Advanced Communications -14.90%-22.13%0.58%

22.5% of Tristel shares are owned by institutional investors. Comparatively, 11.1% of BATM Advanced Communications shares are owned by institutional investors. 21.0% of Tristel shares are owned by company insiders. Comparatively, 30.4% of BATM Advanced Communications shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Summary

Tristel beats BATM Advanced Communications on 9 of the 14 factors compared between the two stocks.

How does Tristel compare to Akers Biosciences?

Tristel (LON:TSTL) and Akers Biosciences (LON:AKR) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their valuation, analyst recommendations, media sentiment, earnings, risk, dividends, profitability and institutional ownership.

Tristel has a net margin of 15.88% compared to Akers Biosciences' net margin of 0.00%. Tristel's return on equity of 23.64% beat Akers Biosciences' return on equity.

Company Net Margins Return on Equity Return on Assets
Tristel15.88% 23.64% 9.89%
Akers Biosciences N/A N/A N/A

22.5% of Tristel shares are owned by institutional investors. 21.0% of Tristel shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Tristel has higher revenue and earnings than Akers Biosciences. Akers Biosciences is trading at a lower price-to-earnings ratio than Tristel, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Tristel£49.54M4.07£6.54M£16.2425.91
Akers Biosciences£2.32M0.00N/A-£129.60N/A

In the previous week, Tristel's average media sentiment score of 0.00 equaled Akers Biosciences'average media sentiment score.

Company Overall Sentiment
Tristel Neutral
Akers Biosciences Neutral

Tristel currently has a consensus price target of GBX 400, suggesting a potential downside of 4.95%. Given Akers Biosciences' higher probable upside, analysts plainly believe Akers Biosciences is more favorable than Tristel.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Tristel
0 Sell rating(s)
1 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
2.00
Akers Biosciences
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

Summary

Tristel beats Akers Biosciences on 9 of the 10 factors compared between the two stocks.

How does Tristel compare to Omega Diagnostics Group?

Omega Diagnostics Group (LON:ODX) and Tristel (LON:TSTL) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their earnings, profitability, analyst recommendations, dividends, media sentiment, risk, valuation and institutional ownership.

Tristel has higher revenue and earnings than Omega Diagnostics Group. Omega Diagnostics Group is trading at a lower price-to-earnings ratio than Tristel, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Omega Diagnostics Group£7.55M0.00-£3.17M-£0.01N/A
Tristel£49.54M4.07£6.54M£16.2425.91

Omega Diagnostics Group has a beta of 3.85, suggesting that its share price is 285% more volatile than the S&P 500. Comparatively, Tristel has a beta of 0.289, suggesting that its share price is 71% less volatile than the S&P 500.

In the previous week, Omega Diagnostics Group's average media sentiment score of 0.00 equaled Tristel'saverage media sentiment score.

Company Overall Sentiment
Omega Diagnostics Group Neutral
Tristel Neutral

Tristel has a consensus price target of GBX 400, suggesting a potential downside of 4.95%. Given Omega Diagnostics Group's higher probable upside, research analysts plainly believe Omega Diagnostics Group is more favorable than Tristel.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Omega Diagnostics Group
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
Tristel
0 Sell rating(s)
1 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
2.00

29.8% of Omega Diagnostics Group shares are held by institutional investors. Comparatively, 22.5% of Tristel shares are held by institutional investors. 50.6% of Omega Diagnostics Group shares are held by insiders. Comparatively, 21.0% of Tristel shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Tristel has a net margin of 15.88% compared to Omega Diagnostics Group's net margin of -51.15%. Tristel's return on equity of 23.64% beat Omega Diagnostics Group's return on equity.

Company Net Margins Return on Equity Return on Assets
Omega Diagnostics Group-51.15% -29.14% -10.53%
Tristel 15.88%23.64%9.89%

Summary

Tristel beats Omega Diagnostics Group on 8 of the 12 factors compared between the two stocks.

Get Tristel News Delivered to You Automatically

Sign up to receive the latest news and ratings for TSTL and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding TSTL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

TSTL vs. The Competition

Export
MetricTristelMedical Instruments & Supplies IndustryMedical SectorLON Exchange
Market Cap£201.72M£2.83B£6.25B£2.73B
Dividend Yield3.51%2.00%2.74%6.11%
P/E Ratio25.9116.6129.24365.27
Price / Sales4.0783.80504.6887,989.37
Price / Cash20.96146.5443.3027.89
Price / Book6.162.359.677.39
Net Income£6.54M£99.80M£3.55B£5.89B
7 Day Performance6.12%0.73%3.02%1.15%
1 Month Performance14.59%2.63%5.13%5.27%
1 Year Performance12.22%-7.14%38.78%80.15%

Tristel Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
TSTL
Tristel
N/AGBX 420.84
+2.6%		GBX 400
-5.0%		+13.7%£201.72M£49.54M25.91208
AMS
Advanced Medical Solutions Group
1.7655 of 5 stars		GBX 243
-1.6%		GBX 270.25
+11.2%		+17.6%£525.86M£228.94M53.7610
SPEC
INSPECS Group
0.5853 of 5 stars		GBX 82
-1.8%		GBX 60
-26.8%		+108.8%£83.37M£195.28MN/A1,673
BVC
BATM Advanced Communications
0.6104 of 5 stars		GBX 13.45
-0.4%		N/A-4.9%£45.74M£123.20MN/A980
AKR
Akers Biosciences
N/AN/AN/AN/A£21.64M£2.32MN/A120

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (LON:TSTL) was last updated on 5/6/2026 by MarketBeat.com Staff.
From Our Partners
Your book attached
Your Download Link (Expiring) If you still haven't downloaded the free Simple Options Trading For Beginners...
Profits Run | Sponsoredtc pixel
Iran's New Leader Just Said Something That Should Terrify Every American
Iran's Supreme Leader has declared the Strait of Hormuz closed as leverage against the U.S. - and with 40% of ...
American Alternative | Sponsoredtc pixel
I’m sounding the alarm
Meta is cutting 10% of its workforce. Microsoft offered voluntary retirement to 7% of U.S. employees. Oracle, ...
Porter & Company | Sponsoredtc pixel
PH: Do THESE 4 things to your bank account now …
In a few short months, the US government could gain unprecedented powers over personal bank accounts - includi...
Weiss Ratings | Sponsoredtc pixel
Satellite Images Spot Potential $10 Trillion Discovery
'Dark Energy': Elon Musk's Next Potential $10 Trillion Move A highly secure site in West Texas now houses a...
Altimetry | Sponsoredtc pixel
My feud with Zohran Mamdani
Emmy-winning analyst releases his next big story Whitney Tilson shocked the nation on 60 Minutes when he ac...
Stansberry Research | Sponsoredtc pixel
A U.S. Resource Gap Is a National Issue - and Opportunity
America still does not domestically produce one mineral tied to batteries, energy storage, and national defens...
i2i Marketing Group, LLC | Sponsoredtc pixel
How to collect $1,170/month from silver
There is a silver fund paying up to 20% in yearly distributions - no mining stocks, no options required. The s...
Investors Alley | Sponsoredtc pixel